Retinal vein occlusion (RVO) is the second most common vision-threatening disorder that happens due to retinal vascular disease. If left untreated, RVO can result in vision impairment and a signifi...
Designing a universal flu vaccine by focusing on the immune system A universal flu vaccine that can foster protection to people against any influenza strain is considered a goal in flu research as it could spare scientists from the often erroneous process of predicting the circulating strains each year and...
Find MoreFDA rejects BioMarin's gene therapy and Gilead's filgotinib over concerns The FDA refused to approve BioMarin's hemophilia A gene therapy valoctocogene roxaparvovec. The U.S. regulator that had earlier told there was no requirement of an AdComm for the drug, aka, valrox, has issued a complete response (CRL) lett...
Find MoreResearchers call out Gilead over the diversity of remdesivir trials Researchers have challenged the sponsors of COVID-19 clinical trials to run more diverse studies. The call follows an evaluation of Gilead’s remdesivir clinical trials, which found the studies that flunked to offer an equal representation of Bla...
Find MoreMorphoSys, Incyte gets an early FDA nod for Monjuvi, an alternative to CAR-T for B-cell malignancies MorphoSys and Incyte announced the US FDA approval under accelerated approval for their treatment Monjuvi in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymp...
Find MoreRoche bets USD 120 Million on UCB's anti-tau Alzheimer's antibody The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB's anti-tau antibody development. If everything goes according to plan, milestone payments and royalties could bring the deal's total near to USD 2 billion. Th...
Find MoreThe Frontotemporal dementia market is expected to increase with a CAGR of 21.41% for 7MM during the study period. However, pharma companies such as TauRx Therapeutics, Axon Neuroscience SE, Prevail Therapeutics, Avid Radiopharmaceuticals, and Alector are actively working to buildup the Frontotemporal dementia pipel...
Find MoreAmylyx Pharmaceuticals grabs USD 30 Million Amylyx Pharmaceuticals has grabbed USD 30 million boosts after posting positive data, which showed it could help decrease amyotrophic lateral sclerosis (ALS). AMX0035, which is its leading candidate, is being tested in degenerative ALS and Alzheimer’s disease....
Find MoreRegeneron recognizes new combos to boost I-O drug Libtayo's cancer response PD-1/L1 inhibitors work by enhancing the immune response to cancer, have benefitted patients combat several types of tumors. However, many people either do not respond to these checkpoint inhibitors, or they eventually develop resistance...
Find MoreAlzheimer's is a progressive brain disorder that results in the degeneration of brain cells. It affects the thinking, reasoning, memory, and problem-solving skills of the person. Apart from cognitive function, it also influences mood, personality, behavior, and social skills. In the advanced stages, the patients ar...
Find MoreToday, Artificial Intelligence has been used effectively in data processing, drug discovery, aiding .....
Find MoreAcute ischemic stroke (AIS) is a medical emergency caused by decreased blood flow to the brain, whic.....
Find MoreCocaine Use Disorder (CUD) is characterized as a substance use disorder in which biological, psychol.....
Find MoreOver the years, the Oncology domain has experienced the entry of several treatment approaches. Thera.....
Find MoreTinnitus is a condition where a person experiences different kinds of noises in one or both ears. It.....
Find MoreGene Therapy has shown tremendous growth in the past few years. The use of AAV (adeno-associated vir.....
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.